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Polymorphous ventricular tachycardia occurred in 1.3% of
patients (5 of 391) who received intracoronary papaverine
over a 47 month period. The arrhythmia lasted <1 min in
all five patients, converting spontaneously in four and
requiring electrical cardioversion in one. Ventricular
tachycardia occurred in 4.4% of women (4 of 90) and 0.3%
of men (1 of 301) (p < 0.0025). Only one of the patients with
ventricular tachycardia had coronary artery disease.
To determine whether other clinical or procedural fac-
tors predispose patients to this side effect of papaverine,
these 5 patients were compared with 25 control patients
who were matched for gender and extent of coronary artery
disease. The following variables were analyzed: age, base-
Intracoronary injection of papaverine in humans has been
shown to produce a maximal hyperemic response in the
coronary circulation that is brief in duration with very little
effect on heart rate and mean arterial pressure (1,2). The
dosage required to produce this response has been estab-
lished. These advantages of intracoronary papaverine have
made it quite useful in the measurement of coronary flow
reserve in the cardiac catheterization laboratory.
In addition to its coronary vasodilating effect, papaverine
is known to produce cardiac electrophysiologic changes. In
1941, Lindner and Katz (3) suggested that papaverine length-
ened the ventricular refractory period. More recently, Ma-
homed et al. (4) noted that papaverine caused changes in the
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line serum potassium and calcium levels, left ventricular
ejection fraction, baseline heart rate, mean arterial pres-
sure, corrected QT interval, the change in corrected QT
interval produced by papaverine and the maximal dose of
the drug per kilogram of body weight. Of these variables,
only baseline heart rate differed significantly in the two
groups of patients.
Thus, polymorphous ventricular tachycardia is an in-
frequent, but important, side effect of papaverine that is
usually self-limited. Women with a relatively slow heart
rate appear to be predisposed to this side effect.
(J Am CoU CardioI1990;15:275-8)
ST-T configuration and prolongation ofthe QT interval when
injected into coronary bypass grafts.
Isolated cases of ventricular tachycardia (1,5) and ven-
tricular fibrillation (6) have been described after administra-
tion of intracoronary papaverine to awake patients. How-
ever, very little is known about the true incidence of serious
ventricular arrhythmias after papaverine. Are these ventric-
ular arrhythmias dose dependent? Are certain patients more
likely to develop this side effect? The present study was
undertaken to assess the incidence of ventricular arrhyth-
mias related to intracoronary papaverine and to determine
whether any clinical or procedural characteristics predispose
patients to this important side effect.
Methods
Study patients. Between October 1984 and June 1988,
intracoronary papaverine was given to 391 patients (90
women, 301 men) at our institution as part of the assessment
of coronary flow reserve. Informed cdnsent for the flow
reserve studies was obtained from each patient. All research
studies were approveq by the Human Use Committee ofthe
University of Iowa. Five of the patients (three women with
0735-1097/90/$3.50
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Figure 1. Recordings from a 56 year old woman who developed
polymorphous ventricular tachycardia approximately 25 s after
injection of 10 mg ofpapaverine into the left coronary artery. Shown
are the baseline surface electrocardiogram (ECG) and aortic pres-
sure recorded at the initiation of the cardiac catheterization proce-
dure and during polymorphous ventricular tachycardia. The ar-
rhythmia converted spontaneously after approximately 8s to regular
sinus rhythm with a prolonged QT interval.
normal coronary arteries, one woman with single vessel
disease and one man with normal coronary arteries) devel-
oped polymorphous ventricular tachycardia immediately af-
ter an injection of the drug. Each of these five patients was
matched for gender and extent of coronary disease with five
other patients who received the drug but did not develop the
arrhythmia. Thus, the control group consisted of 25 patients.
Clinical characteristics analyzed. The following variables
were compared in patients who developed ventricular tachy-
cardia and patients in the control group: age, serum potas-
sium, serum calcium, left ventricular ejection fraction, base-
line heart rate, baseline mean arterial pressure, baseline
corrected QT interval and the change in corrected QT
interval induced by papaverine.
Left ventricular ejection fraction was measured by con-
trast ventriculography or radionuclide ventriculography in
most patients. Serum potassium level was measured within 1
to 4 days preceding the catheterization, and serum calcium
was measured from 1 to 6 days before the procedure.
Baseline heart rate and corrected QT interval were
measured from a six lead surface electrocardiogram at the
initiation of the cardiac catheterization procedure. Corrected
QT intervals was calculated by Bazett's formula (7) as
follows:
QT
QTc = yRR'
Baseline mean arterial pressure was measured from a sheath
in the femoral artery immediately after sheath placement.
The change in corrected QT interval was calculated as the
difference between the baseline corrected QT and the cor-
rected QT measured immediately after the first dose of
papaverine (in the control group) or after restoration of
regular sinus rhythm (in patients who developed ventricular
tachycardia).
Procedural factors analyzed. The coronary artery in-
jected with papaverine was recorded in all patients. In
addition, the number of injections and the amount of papav-
erine administered per injection were recorded. The maxi-
mal dose of the drug received by each patient was calculated
by using the largest injection per kilogram of body weight.
Statistical analysis. All values reported are mean values
± SEM. Chi-square analysis was used to determine differ-
ences between the proportions of women and men who
developed ventricular tachycardia as a side effect of the
drug. Other clinical and procedural characteristics were
compared with use of Student's t test for unpaired data.
Probability values <0.05 were considered statistically signif-
icant.
Results
Figures 1 and 2 are recordings from one of the five
patients who developed ventricular tachycardia. In all five
such patients, the arrhythmia lasted <1 min, and it con-
verted spontaneously in four patients (one patient required
electrical cardioversion). No other side effects of papaverine
were noted, and there were no clinical sequelae in any
patient.
Gender-based difference in incidence. In the total group of
patients who received papaverine, the proportion of women
who developed ventricular tachycardia was 4 of 90 (4.4%)
and the proportion of men who had this side effect was 1 of
301 (0.3%). These proportions differed significantly (p <
0.0025).
Influence of clinical characteristics (Table 1). In all pa-
tients serum potassium levels were within the normal range
of 3.5 to 5.0 mEq/liter. Only one reported serum calcium
level (in a control patient with a level of 8.3 mg/dl) was
slightly below the normal range of 8.5 to 10.5 mg/dl.
Left ventricular ejection fraction was measured in 18 of
the 25 control patients and 3of the 5patients with ventricular
tachycardia. Ejection fraction was normal (2':50%) in all
patients.
The mean heart rate was 57 ± 5 beats/min in the patients
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Table 1. Clinical Characteristics of Patients in the Ventricular
Tachycardia Group and the Control Group
*p < 0.05. Values are mean values ± SEM. CaH = serum calcium;
HR = heart rate; K+ = serum potassium; LVEF = left ventricular ejection
fraction; MAP = mean arterial pressure; QTc-pre = baseline corrected QT
interval; llQTc = change in corrected QT interval produced by papaverine.
Figure 2. Recordings, from the same patient as described in Figure
1, showing phasic and mean coronary flow velocity and the surface
ECG during the initiation of polymorphous ventricular tachycardia.
A6 mg dose of intracoronary (Lc.) papaverine administered 3 min
earlier had produced QT interval prolongation without arrhythmia.
The corrected QT interval before the 10 mg dose was 0.55 s. Discussion
In this study, the incidence of polymorphous ventricular
tachycardia was 1.3% among patients receiving intracoro-
nary papaverine for the study of their coronary reserve.
Women with a relatively slow heart rate were predisposed to
developing this side effect. Because papaverine prolongs the
QT interval, the link between a slow heart rate and the
arrhythmia is not surprising. Several studies (8,9) have
established that drug-induced QT prolongation combined
with bradycardia predisposes to polymorphous ventricular
tachycardia.
Other drugs that prolong the QT interval and thus predis-
pose to polymorphous ventricular tachycardia are antiar-
rhythmic agents (especially quinidine), phenothiazines and
tricyclic antidepressants (9). These drugs cannot be impli-
cated in the present study because only one patient (in the
control group) received a drug in these categories (amitrip-
tyline) in the 24 h preceding the cardiac catheterization.
Possible mechanism. The mechanism by which papaver-
ine causes this arrhythmia is uncertain. One possible expla-
nation is that the selective coronary injection of papaverine
aggravates the dispersion of ventricular repolarization,
which is already present at slow heart rates (8,9).
Comparison with other coronary vasodilators. Polymor-
phous ventricular tachycardia is the only major side effect of
papaverine. Other coronary vasodilators also have serious
adverse effects. Intracoronary administration of hyperosmo-
lar ionic contrast medium is known to produce adverse
hemodynamic effects (10). Ionic contrast medium also pro-
longs the QT interval and can produce sinus arrest, heart
block and ventricular fibrillation (11,12). Intravenous dipyr-
idamole is associated with two serious but infrequent side
change in corrected QT interval was not significantly dif-
ferent in the two groups.
Influence of procedural factors. The left coronary artery
was the artery injected with papaverine in all 5 patients who
developed ventricular tachycardia and in 22 of the 25 control
patients. In two control patients, papaverine was adminis-
tered into the right coronary, and in one patient the drug was
injected into both the left and the right coronary arteries.
In the ventricular tachycardia group, patients received 1
to 4 injections of papaverine; the amount of papaverine
administered per injection varied from 6 to 10 mg. The
maximal dose of papaverine ranged from 0.07 to 0.18 mglkg
(mean, 0.14 ± 0.02). In the control group, the number of
injections per patient varied from 1 to 9, and the amount of
papaverine per injection varied from 4 to 12 mg. The range of
the maximal dose of the drug was 0.07 to 0.21 mglkg (mean,
0.13 ± 0.01). These values did not differ significantly from
values in the ventricular tachycardia group. Thus, the total
dose, maximal dose per kilogram and dose sequences were
unrelated to the development of ventricular tachycardia.
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100 ± 2
0.42 ± 0.01
+0.12 ± 0.04
Ventricular
Tachycardia Group
(n = 5)
~l
Papaverine 10 mg i.c.
53.7 ± 1.7
4.13 ± 0.07
9.11 ± 0.10
69 ± 2.1
69 ± 2
98 ± 3
0.41 ± 0.01
+0.09 ± 0.02
Control Group
(n = 25)
~
1 sec
Lead II ECG
Phasic
tCoronary FlowVelocity(kHz Shift) 0-
Flow Catheter
Mean Removed
Coronary Flow !\Velocity 0-(kHz Shift)
who developed ventricular tachycardia and 69 ± 2 beats/min
in the control group, a statistically significant difference. The
baseline corrected QT interval of the ventricular tachycardia
group was 0.42 ± .01 s and of the control group was 0.41 ±
0.01 s, and there was no significant difference between the
two groups. All of the ventricular tachycardia patients had
an increase in corrected QT interval after papaverine (mean
L.QTc = + 0.12 ± 0.04 s). Only three control patients
showed no change or a slight decrease in corrected QT
interval after papaverine; the majority showed an increase
(mean L.QTc = + 0.09 ± 0.02 s). The papaverine-induced
Age (yr)
K+(mEqlIiter)
Ca2+ (mg/dl)
LVEF(%)
Baseline HR (beats/min)
Baseline MAP (mm Hg)
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effects, acute myocardial infarction (fatal and nonfatal) with
an incidence rate of 0.1% and bronchospasm with a 0.2%
incidence rate (A. Ranhosky, Boehringer Ingelheim Pharma-
ceuticals, Inc., verbal communication, February 1989). One
preliminary study (13) of intracoronary injection of adeno-
sine reported that 3 of 12 patients who received adenosine
developed symptomatic bradyarrhythmia, atrioventricular
block or asystole.
Conclusions. Papaverine is a relatively safe and quite
useful coronary vasodilator for measuring coronary flow
reserve. Polymorphous ventricular tachycaJ;dia is an impor-
tant, yet infrequent, side effect of its administration. Al-
though women are more prone to developing this side effect,
all patients should be closely monitored while receiving
intracoronary papaverine. There are no quantitative data in
patients with preexisting ventricular arrhythmias, but ex-
treme caution should be employed when the drug is admin-
istered to this group of patients.
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